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Plasma cells are heterogenous in terms of their origins, secretory products, and lifespan.
A current paradigm is that cell cycle exit in plasma cell differentiation is irreversible, follow-
ing a pattern familiar in short-lived effector populations in other hemopoietic lineages. This
paradigm no doubt holds true for many plasma cells whose lifespan can be measured in
days following the completion of differentiation. Whether this holds true for long-lived bone
marrow plasma cells that are potentially maintained for the lifespan of the organism is less
apparent. Added to this the mechanisms that establish and maintain cell cycle quiescence
in plasma cells are incompletely defined. Gene expression profiling indicates that in the
transition of human plasmablasts to long-lived plasma cells a range of cell cycle regulators
are induced in a pattern that suggests a quiescence program with potential for cell cycle
re-entry. Here a model of relative quiescence with the potential for replicative self-renewal
amongst long-lived plasma cells is explored. The implications of such a mechanism would
be diverse, and the argument is made here that current evidence is not sufficiently strong
that the possibility should be disregarded.
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INTRODUCTION
Entry into cell cycle quiescence accompanies the final phenotypic
maturation of plasma cells (1). In short-lived plasma cells the
maintenance of quiescence is rendered irrelevant by cell death. In
contrast long-lived plasma cells may potentially survive for the
lifetime of the organism (2, 3), and the mechanisms maintaining
quiescence in such populations are of much greater significance.
The current paradigm holds that cell cycle exit is permanent and
irreversible for all plasma cells (2, 4, 5). However it may be timely
to re-evaluate this paradigm and consider an alternate possibil-
ity: that long-lived “memory” plasma cells adopt a quiescent state,
controlled by their niche environment, but maintain the potential
for replicative self-renewal through cell division. The implications
of such a mechanism are diverse, and the evidence against is
potentially not sufficiently strong that the possibility should be
disregarded. Recent progress in generating and maintaining long-
lived human plasma cells in vitro may help to address some aspects
of this issue.
DISCUSSION
LIFESPAN OF PLASMA CELLS
The nature of plasma cell lifespan and the concept of irreversible
cell cycle exit accompanying terminal differentiation are inter-
twined. Early observations of potential plasma cell longevity were
largely set aside in favor of the view of continuous generation
of short-lived plasma cells (6, 7); and in the context of cell
cycle exit coupled to functional differentiation, and imminent
cell death the concept of irreversible cell cycle exit is natural and
follows the prevailing pattern in other short-lived hemopoietic
effectors.
The critical transition in our understanding of plasma cell
longevity came with the studies of Manz et al. (8) and Slifka et al.
(7), whose works combined to provide proof of the existence of
long-lived plasma cells, which preferentially resided in the bone
marrow and made a central contribution to long-term humoral
immunity. Subsequent work from other labs in mouse models
has also pointed to extended lifespans, although the half-life pre-
dictions vary somewhat with the type of assay and vaccination
strategy employed, and in recent data include dynamic changes
in long-lived plasma cells in response to systemic inflammation
(5, 9, 10). In earlier continuous tritiated-thymidine incorpora-
tion studies in rat, antibody-secreting cells in the bone marrow
showed more general labeling reaching near 40% by 10 days (11),
but it has been argued that these experiments may have over-
looked long-lived quiescent plasma cells since antigen-specific
populations were not assessed (12).
Serological studies in human combined with the persistence of
plasma cells after therapeutic B-cell depletion point to significant
lifespans for human bone marrow plasma cells (13). While direct
evidence of plasma cell longevity in man is limited, in vitro gener-
ated human plasma cells can certainly persist as non-dividing cells
for months (14). A view of the bone marrow plasma cell compart-
ment, encompassing the decay of antibody titers after therapeutic
B-cell depletion, would include a heterogenous mix of plasma cell
populations, many with relatively short half-lives in the region of
<100 days, as well as populations of longer-lived cells persisting
well beyond this time-frame. In human bone marrow such hetero-
geneity is potentially reflected in phenotypic differences in bone
marrow plasma cells (G. Arumugakani and A. Rawstron, personal
communication).
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DIFFERENTIATION AND THE PERMANENCE OF CELL CYCLE EXIT
While the shift toward a general acceptance of long-lived bone
marrow plasma cell has occurred, the paradigm that all plasma
cells have irrevocably exited cell cycle has remained (2, 4, 5). Ter-
minal differentiation as a concept encompasses the acquisition of
high functional specialization and the loss of potential for alternate
cell fates. This is frequently linked to irrevocable cell cycle exit. This
clearly pertains in the context of short-lived effector cells that die
soon after completing differentiation and exiting cell cycle. In con-
trast in long-lived cells functional specialization is not necessarily
linked to irrevocable cell cycle exit (15–19). Schwann cells provide
a well-studied example of cells with high functional specialization
that enter a quiescent rather than post-mitotic state, and can re-
enter cell cycle in response to injury or growth factor stimulation
(18). However the ability of differentiated cell populations to re-
enter cell cycle also extends to other systems traditionally viewed
as terminally differentiated such as cardiac myocytes (15, 16, 19).
Recently such concepts have also been extended to tissue resident
macrophage populations (20–22). Given that such examples exist
in other tissues with complex organization, and in immunological
populations conventionally viewed as deriving from hemopoietic
repopulation, it is reasonable to re-evaluate the paradigm that all
differentiated plasma cells have necessarily exited cell cycle in an
irrevocable fashion.
While there is little evidence directly in support of long-lived
plasma cells undergoing self-renewal by cell division there is also
relatively scant data in direct opposition. Several early studies
demonstrated that plasma cells but not their proliferating precur-
sors were resistant to hydroxyurea in short-term cultures (23–25).
This is consistent with cell cycle exit, but does not distinguish the
nature of this quiescence. Phenotypically mature human plasma
cells generally lack Ki67 expression by flow cytometry (26), but
low levels of proliferating plasma cells are detectable (27), equally
flow cytometry only identifies a small fraction of hemopoietic stem
cells (HSCs) as detectably in cell cycle (28). The need for long-lived
plasma cell renewal may be different in organisms with extended
lifespans and longer intervals to sexual maturity, but in the murine
studies a slight accumulation of BrdU-labeled antigen-specific
plasma cells over time appears to be present in the continuous
feeding arm of the original Manz et al. study (8). Additionally
an interesting recent study examined pulsed BrdU incorporation
into bone marrow plasma cells under a range of immunization
scenarios (5). At 60 and 100 days after primary immunization a
very low, but above background, level of BrdU incorporation into
antigen-specific plasma cells appears to be present. While such
data can be interpreted in the context of the prevailing paradigm
as newly formed plasma cells arising from B-cell differentiation, it
can also be argued that the cell of origin from which a BrdU-labeled
plasma cell derives is not known in such studies, particularly after
an extended period post immunization. Some or all of the BrdU
labeling could derive from incorporation into pre-existing plasma
cells that arose following the initial immunization.
CELLULAR RELATIONSHIPS, THE NICHE, AND CELL CYCLE
Under a range of experimental conditions the process of cell cycle
exit during plasma cell differentiation occurs in an orderly fash-
ion (14, 29–31), suggesting that the core mechanism is a common
feature shared by all plasma cells regardless of cell of origin or
activating stimulus. Whether such consistency pertains to the
maintenance of cell cycle exit in differentiated plasma cells is less
certain. The ability of cellular environment to influence plasma cell
biology is a central theme of long-term plasma cell survival and the
bone marrow plasma cell niche is critical to the persistence of these
cells (32, 33). This niche is in part defined by stromal cells that also
support multipotent hemopoietic precursors (34). In addition to
stromal cells many more fluctuant hemopoietic populations have
been implicated as contributing factors to plasma cell survival (34–
38). This complexity has been summarized in the concept of the
multicomponent plasma cell niche (39).
For the principle other long-lived quiescent bone marrow pop-
ulation, the HSC, a remarkably close relationship exists between
the niche environment and quiescent state, with a range of niche
factors implicated in maintaining quiescence (40–44). Using HSCs
as an example, if replicative self-renewal can occur in plasma cells
then it is likely that triggers will include changes in niche factors
that link quiescence to survival, and physiologic signals that pro-
mote transient proliferation. If both quiescence and survival are
directly linked to niche occupancy, then the partial displacement
of a long-lived plasma cell from its niche, or the depletion of lim-
iting niche factors by competing populations could represent a
trigger for replicative self-renewal.
CELL CYCLE IN PLASMA CELL DIFFERENTIATION
In general clonal expansion precedes plasma cell differentiation
representing an intrinsic feature of an effective immune response.
In model systems plasma cell differentiation is a process directly
linked, at a mechanistic level, to cell division (23, 45–47). Indeed
whether plasma cell differentiation can occur in the absence of
cell division is uncertain. Elegant modeling approaches indicate
that the fate adopted by differentiating B-cells is determined in a
stochastic fashion linked to cell division (48).
While cell division is thus an essential component of the plasma
cell differentiation program, this program does not complete if exit
from cell cycle is prevented (1, 30). This is not a unique feature
of plasma cell differentiation, but a general one of differentiation
programs. Indeed much more is known of how cell cycle control
intersects with transcriptional programs of cellular differentiation
in other lineages (49). General features are that control of G1 pro-
gression and regulators of the RB/E2F pathway are central to these
processes, but show lineage specific relationships. Furthermore cell
cycle regulators can directly impact on transcriptional regulation
and the execution of differentiation programs (49).
Direct experimental evidence indicating that cell cycle exit is
necessary for plasma cell differentiation comes from analysis of
p18INK4C, whose presence in differentiating B-cells is essen-
tial for plasma cell differentiation (30). p18INK4C (CDKN2C)
is a repressor of the CyclinD-CDK4/6 complex and thus controls
the initial phosphorylation of RB which is required for subse-
quent hyperphosphorylation by Cyclin-E-CDK complex and G1/S
progression (1). CDKN2C is induced in parallel with BLIMP1
(PRDM1), the principle transcription factor defining the commit-
ted transition to plasma cell differentiation (50). CDKN2C defi-
cient B-cells induced to undergo plasma cell differentiation express
BLIMP1 and initiate the gene expression program of plasma cell
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differentiation, but fail to complete the process of differentiation
appropriately, and never achieve the high secretory activity of ter-
minally differentiated plasma cells (30). In a more recent analysis
the same laboratory has extended these investigations to exam-
ine the transition of highly proliferative “intermediate plasma
cells” to mature plasma cells, the former cell state being similar to
plasmablasts. CDKN2C was progressively induced from activated
B-cell to intermediate and then mature plasma cell state, while
CDKN1B (p27KIP1) was selectively induced in mature plasma
cell in which both CYCLIN-D2 and -E were also maintained (50).
Failure to induce CDKN2C led to cell death amongst“intermediate
plasma cells.” These data suggest that cell cycle inhibitors may act
sequentially in the differentiation process, and indicate that apop-
totic pathways provide a fail-safe controlling plasmablast that do
not appropriately exit cell cycle.
A direct link between the differentiation program and cell cycle
exit also lies in the ability of BLIMP1 to repress MYC (51, 52).
BLIMP1 expression accumulates with time during plasma cell dif-
ferentiation (53), and is well established as a critical regulator of
this process necessary to mediate the genetic reprograming from
B-cell to plasma cell (54, 55). BLIMP1 is implicated in the repres-
sion of multiple targets associated with cell proliferation (54), and
can bind at the promoters of genes associated with kinetochore
function (SPC25 and CENPH ) (56), which are also repressed
at the plasmablast to plasma cell transition (14), providing an
additional mechanism by which it may impact on cell division
in plasma cells. Expression of BLIMP1 accumulates during dif-
ferentiation, precedes the entry into cell cycle quiescence, and is
abundantly expressed in mouse and human proliferating plas-
mablast populations (14, 31, 50, 53). BLIMP1 can recruit several
different chromatin modifiers (57–59), which together provide
the potential for either labile or stable epigenetic regulation. In
a cumulative expression model the gradual increase of BLIMP1
may be linked to sequential and progressively more stable extinc-
tion of different gene expression programs. Under such a model
the proliferative program would represent a late target repressed
once BLIMP1 levels pass a particular threshold at the plasmablast
stage. The inability of BLIMP1 to compensate for p18INK4C (50),
suggests that the role of BLIMP1 in cell cycle control could lie on
the one hand in attenuating the impetus for cell cycle progression
and on the other in reinforcing the decision through epigenetic
repression of proliferation genes. Nonetheless at present little is
known of how the transcriptional program of plasma cell differ-
entiation intersects with the machinery of cell cycle control and
exit. While BLIMP1 acts as a regulator of terminal differentiation
in both B- and T-cell lineages (55, 60, 61), this transcription factor
can also play roles in cellular populations with stem cell properties
(62–65). Thus BLIMP1 expression per se is not necessarily strictly
linked to irreversible cell cycle exit.
BLIMP1, BCL6, AND MYELOMA PLASTICITY
During B-cell differentiation BLIMP1 is involved in counter-
regulatory relationships with PAX5 (66–68), SPIB (54, 69), and
BCL6 (54, 70, 71). These regulatory interactions may be fur-
ther modified by BACH2 dependent BLIMP1 repression (72–75).
Together these interactions play critical roles in limiting and mod-
ulating PC differentiation. A notable feature of the “intermediate
plasma cells” generated during murine splenic immune responses,
was the apparent co-expression of BLIMP1 and BCL6 in a sig-
nificant fraction of cells (9%), when analyzed at single cell level
(50). However this co-expression was likely to represent a transient
state as most cells expressed either factor in a mutually exclusive
fashion. Interestingly, in a myeloma cell line model co-expression
of BCL6 and MTA3 can drive a phenotypic reversion with B-cell
antigen expression (76). Although evidence for BCL6 expression
in primary myeloma is limited, some evidence of expression has
been observed (77). While BCL6 expression and phenotypic rever-
sion may provide an explanation for observations in advanced
myeloma, and myeloma cell lines, it is important to distinguish
between such transformed states and those operating in normal
plasma cells, and early plasma cell neoplasms. In cell lines and
advanced myeloma several co-operating oncogenic events con-
tribute to extensive cell cycle deregulation (78, 79). In addition
loss of epigenetic control, with a global increase in DNA hypo-
methylation, is a feature of the monoclonal gammopathy of unde-
termined significance (MGUS) to myeloma transition (80). Cell
proliferation itself imposes a burden on maintaining epigenetic
regulation, requiring the re-establishment of appropriate control
with each division (81). Thus rapid proliferation is likely to con-
tribute to plasticity of gene expression in advanced myeloma, and
may be intrinsically linked to reversion to an “intermediate plasma
cell” or plasmablast-like state. Indeed in some instances patients
present de novo with disease that blurs the boundaries between
“plasmablastic myeloma” and “plasmablastic lymphoma,” leading
to significant diagnostic and therapeutic questions (82). How-
ever, in normal plasma cells, and early neoplasia the balance is
strongly in favor of maintaining appropriate epigenetic control
and if cell cycle re-entry does occur, then limiting the frequency
of this event. Thus, while consideration of phenotypic plastic-
ity and its transcriptional control is relevant in advanced plasma
cell malignancies, this must be distinguished from the control
processes potentially operating in normal plasma cells, and early
plasma cell malignancy under consideration here.
NUCLEAR ORGANIZATION AS A LINK TO STABLE CELL CYCLE EXIT
A classical feature of mature plasma cells is the organization of the
nucleus such that dense chromatin condensation is observed in a
ring like pattern at the nuclear periphery (83). This generates the
“clock-face” nucleus of the mature plasma cell. The significance
of this nuclear architecture is unknown, but compaction of hete-
rochromatin can provide a mechanism contributing to stable gene
silencing.
A precedent for this in relation to cell cycle exit can be found in
the process of senescence. Cellular senescence is characterized by
the expression of a range of cell cycle control proteins, some but
not all of which are shared with plasma cells, and the reorganiza-
tion of the cell nucleus with compaction of silenced chromosome
domains into senescence associated heterochromatic foci (SAHF)
(84). These domains do not occur in reversibly arrested cells,
and are enriched for E2F target genes (84). SAHFs derive from
the organization of facultative heterochromatin, associated with
tri-methylated H3-K9 and tri-methylated H3-K27, into ordered
structures rather than from epigenetic spreading (85–87). Thus
if the organization of the plasma cell nuclear heterochromatin
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can be shown to resemble that of SAHFs and contain E2F tar-
get genes, it would support a process of irreversible cell cycle
exit amongst such cells. If this were the case, failure to estab-
lish such highly ordered nuclear structure would be predicted
amongst long-lived plasma cell that retain the potential for cell
cycle entry, providing a potential mechanistic distinction between
such populations.
GENE EXPRESSION CHANGES ASSOCIATED WITH PLASMABLAST TO
PLASMA CELL TRANSITION
One limiting factor in analyzing plasma cell differentiation has
been the inability to generate and maintain quiescent mature
plasma cells in vitro. The resolution of this problem allowed
analysis of the gene expression changes associated both with the
differentiation and survival of human plasma cells over time (14).
Cell cycle control was amongst the largest and most coherently
regulated genetic programs. As expected, genes linked to cell cycle
progression, mitosis, and cytokinesis were induced in activated B-
cells maintained in plasmablasts and silenced in quiescent plasma
cells. Although mRNA expression is not necessarily an accurate
readout of protein expression and cell cycle control, nonetheless
the gene expression changes linked to the transition from prolifer-
ating plasmablast to quiescent and long-lived plasma cells provide
an indication of the cell cycle state and the potential processes
operating to maintain quiescence (Figure 1).
MYC and CDKN2C
Consistent with the proposed pattern of regulation from prior
studies (52), MYC expression was repressed at the plasmablast to
plasma cell transition. CDKN2C (p18INK4C) followed a pattern
of expression consistent with its role in murine differentiation
being induced initially at the activated B-cell to plasmablast tran-
sition and then further induced at the plasmablast to plasma
cell transition. Interestingly over the following weeks CDKN2C
expression appeared to decay slightly amongst in vitro plasma
cells that maintained cell cycle quiescence, and was expressed at
only very low level in bone marrow derived plasma cell popu-
lations (data not shown) (14). A similar pattern is observed in
data from another analysis of plasma cell associated gene expres-
sion (http://amazonia.transcriptome.eu/) (31). The data in human
plasma cells would suggest therefore that CDKN2C expression is
not maintained.
CDKN1A and CDKN1B
Amongst other negative regulators of the G1/S cell cycle check-
point CDKN1A (p21CIP1/WAF1) was initially modestly expressed
FIGURE 1 | Schematic illustration of selected cell cycle
regulators. The central line diagram provides a broad summary of
relationships between the selected cell cycle regulators as identified
in referenced literature. General positive (arrow heads) and negative
(horizontal lines) regulatory interactions are indicated, without specific
reference to the nature of the regulatory mechanism. The pattern of
mRNA expression of the illustrated cell cycle regulators is shown in
the scatter plots as indicated, with data derived from Cocco et al. (14).
The y -axes show log2 mRNA expression values, the x -axes time in
days, the B-cell (B), Activated B-cell (ABC), Plasmablast (PB), and
Plasma cell (PC) time points are illustrated for the left and right hand
top panels.
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in resting B-cells induced in activated B-cells maintained at slightly
lower level in plasmablasts and then sustained at high level
in plasma cells. CDKN1B (p27KIP1) was expressed in B-cells,
repressed in activated B-cells and induced and then maintained
in plasmablasts and plasma cells. These data would therefore sup-
port the contention that CDKN1B (p27KIP1) co-operates with
CDKN2C (p18INK4C) in contributing to G1/S checkpoint reg-
ulation (50), but suggest that in human plasma cells CDKN1A
also contributes. Given the gradual loss of CDKN2C following
differentiation the expression patterns support the argument that
CDKN1A and CDKN1B are preferentially involved in restraining
cell cycle progression once quiescence is established. Additionally
the interaction of these proteins with the differentiation program
may extend beyond the control of cell cycle. Thus in oligoden-
drocyte differentiation CDKN1B promotes cell cycle exit, while
CDKN1A is linked to expression of the differentiated cell program
in cells which have already exited cell cycle (88).
E2F5 and 6
The expression patterns of CDKN2C and CDKN1A/B at the plas-
mablast/plasma cell transition point reflect the central theme
of G1/S control in cellular differentiation and senescence pro-
grams (49, 89), with common convergence on the control of RB
phosphorylation and repression of E2F transcription factors. The
E2F family includes both activators and repressors of transcrip-
tion, which dimerize with transcription factor DP1 (TFDP1) to
bind at common consensus sequence (90). TFDP1 is dynamically
regulated showing maximal expression in activated B-cells, but
sustained expression at lower levels in plasma cells. The mRNA
for activatory family member E2F2 shows a similar pattern but
with maximal expression in plasmablasts, rather than activated
B-cells, and is progressively repressed with sustained plasma cell
longevity. In contrast the repressive E2F family members E2F5 and
E2F6 are distinguished by maximal expression in plasma cells. Co-
expression of E2F5 and E2F6 in the absence of E2F7 is observed in
quiescent rather than senescent cells (91). While E2F7 can provide
a link between RB and cellular senescence programs (91), E2F7
mRNA was not induced upon plasma cell differentiation.
E2F family members, including E2F6, show extensive overlap
in binding of DNA elements across the genome (92). However
the specific expression of E2F6 mRNA in plasma cells is of inter-
est since E2F6 has been shown to repress E2F and MYC target
genes in G0 in complex with TFDP1 and polycomb group pro-
teins (93). Indeed E2F6 can be found in combination with several
distinct functional partners implicated in the regulation of chro-
matin state such as EZH2, BMI1, and L3MBTL2 (94–96). Each of
these genes is expressed at some level in plasma cells, but BMI1
is notable for showing a progressive increase over time. Thus the
induced expression of E2F6 upon plasmablast to plasma cell dif-
ferentiation may support the maintenance of the quiescent cell
state and has the potential to contribute to epigenetic repression
of cell cycle genes (93, 96).
Cyclins
While Cyclin-E (CCNE) mRNA was induced acutely in activated
B-cells and then repressed, Cyclin-D3 (CCND3) decreased rapidly
during the differentiation. Cyclin-D2 (CCND2) mRNA by contrast
increased rapidly and was maintained at stable levels in quiescent
plasma cells that no longer expressed genes associated with active
cell proliferation. This is similar to the expression pattern reported
in murine plasma cells (50). CDK6 showed a spike of expression
in activated B-cells and plasmablasts and was maintained at low
level in mature plasma cells.
The re-entry from quiescent G0 into the G1 phase of the cell
cycle can be regulated by a CCNC/CDK3 complex (97). While
CDK3 expression was not detected, CDK2 also acts as a potential
alternate CCNC partner (98), and its mRNA was expressed at sim-
ilar levels in plasma cells as in resting B-cells. CCNC can also act in
complex with CDK8 to regulate RNA-polymerase II phosphoryla-
tion (99), but CDK8 mRNA was minimally expressed throughout
the differentiation series. In human HSCs CCNC acts in control
of quiescence, with overexpression of CCNC linked to reduction
and loss of CCNC to enhancement of HSC quiescence (100). It is
therefore notable that CCNC expression increased on transition
from plasmablast to plasma cell state, possibly providing a mech-
anism along with sustained CCND2 mRNA expression, to poise
plasma cells for cell cycle re-entry.
TP53, RB1, and RBL1/2
TP53, RB1 and their homologs are central to pathways of cell cycle
control, and both TP53 and RB dependent pathways co-operate
in the robust cell cycle exit of senescence (89). CDKN1A is a core
TP53 target and its transcriptional up-regulation could be indica-
tive of a TP53 dependent pathway in plasma cells. At mRNA level
TP53 showed modest induction in activated B-cells, at the peak
of proliferative response but was subsequently present at very low
level.
RB1 was expressed at modest levels up to the plasmablast
stage, but decreased at mRNA level on plasma cell maturation.
RBL1 (p107) was minimally expressed throughout differentiation,
while RBL2 (p130) displayed the most sustained expression lev-
els. Interestingly a functional co-operation between CDKN1B and
RBL2 has been identified in hemopoietic cells, and in B-cells com-
bined deficiency of these genes leads to hyper-responsiveness to
mitogenic stimuli (101).
FBXW7 and FOXO3
Beyond genes encoding proteins that are direct controllers of cell
cycle progression and exit, other genes notably induced at the
plasmablast to plasma cell transition include FBXW7 and FOXO3
both of which play important roles in the control of HSCs (102–
104). FBXW7 is a component of the SCF-ubiquitin ligase complex
and is responsible for targeting several cell cycle promoting factors
including MYC and CCNE for degradation (105). Thus expres-
sion of FBXW7 can provide a mechanism to actively control
pro-proliferative stimuli.
The FOXO family of transcription factors, including FOXO3,
is linked to control of cell cycle progression, apoptosis, and stress
resistance (106). FOXO3 can drive cell cycle exit through transcrip-
tional regulation of CDKN1B (p27) and RBL2 (p130) (107), both
of which as noted above are expressed in plasma cells. Additionally
FOXO3 can induce CITED2 (108), a transcriptional co-regulator,
which in HSCs is implicated in cellular survival pathways (109),
and is also induced at the plasmablast to plasma cell transition.
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FOXO3 is itself a target of the PI3K pathway via AKT or SGK1
(110, 111). PI3K signaling is necessary for earlier stages of plasma
cell differentiation (112), but has not been examined in detail in
differentiated plasma cells. If FOXO3 expression is linked to con-
trol of CDKN1B and RBL2 in plasma cells then activation of the
PI3K/AKT pathway may provide one means of promoting cycle
re-entry.
Combined expression pattern
The gene expression changes during human plasmablast to plasma
cell transition and subsequent maintenance are consistent with
the model that cell cycle exit is established through the combined
action of CDKN2C (p18), CDKN1A (p21), and CDKN1B (p27)
(50), with the latter two showing more consistent expression once
cell cycle exit is established. The sustained expression of RBL2
offers a potential direct co-operation with CDKN1B (101). In par-
allel expression of E2F5 and E2F6 provides additional regulators
that can maintain G0 quiescence (90). While FOXO3A identi-
fies a potential upstream control pathway for negative cell cycle
regulators (106), which is known to be responsive to PI3K/AKT
signaling (110), FBXW7 expression provides the potential for
degrading mediators of cell cycle progression (105). In parallel
the up-regulation of CCNC and sustained expression of a poten-
tial CDK partner (CDK2) as well as CCND2 and CDK6 mRNAs,
could comprise a latent trigger for G0/G1 re-entry (97, 98). At
a population mRNA level the induction of plasma cell quies-
cence is therefore associated with expression of several tiers of
cell cycle repressive genes, accompanied by retained expression of
cell cycle activators. This suggests the potential for regulated cell
cycle re-entry.
MONOCLONAL GAMMOPATHY: AN EXPECTED MANIFESTATION OF
SELF-RENEWING PLASMA CELL POPULATIONS?
Prior to the development of aggressive myeloma, the majority of
patients pass through a clinically detected or retrospectively iden-
tifiable period of indolent plasma cell neoplasia (113, 114). At the
earliest stages this is characterized by the presence of a paraprotein
and very low percentages of phenotypically aberrant plasma cells
in the bone marrow, and is known as MGUS (115). The evolution
from indolent to aggressive myeloma is thought to occur with both
linear and branching patterns (79, 116–118).
In the context of the prevailing paradigm of plasma cell differ-
entiation, the irreversible nature and the requirement for cell cycle
exit in order to complete differentiation should oppose malignant
transformation of mature plasma cells. This presents a potential
conundrum when considering the pathogenesis of plasma cell
malignancies, in particular the more indolent precursor states.
There are two principle models of plasma cell malignancy: the
first is that neoplastic plasma cells acquire sufficient oncogenic
deregulation to escape the normal process of cell cycle exit and
thus have the potential to clonally expand and progress over time
(78, 79); the second is that the phenotypic plasma cell population
of the malignancy is supported by a population of clonally related
B-cells that act as tumor progenitors to maintain the myeloma
plasma cell population (119–123). Given the complexity of human
disease, each of these models may pertain in at least some instances.
However while B-cell populations related to the malignant plasma
cell clone are widely described (124, 125), they are not univer-
sally detected (126). Clonotypic B-cells in the peripheral blood
have been found to possess early but not late oncogenic events of
the myeloma clone (127). Furthermore myeloma cells expressing
CD138 maintain the tumor upon transplantation into immun-
odeficient mice (128); and these results have been extended in
recent studies showing that the capacity to establish and sustain
the tumor in immunodeficient mice resides in malignant plasma
cells, some of which lack CD138 expression, but not in clonotypic
B-cells (129–131). Overall therefore there is strong evidence that
in many instances of myeloma the disease is maintained in the
neoplastic plasma cell compartment.
Given that in established myeloma the disease is maintained
amongst plasma cells, earlier indolent plasma cell neoplasms
including MGUS are also likely to be maintained by the neoplas-
tic plasma cells themselves. However in this context the fraction
of cells in cycle is very low, as are the number of transforming
oncogenic events, while the accumulation of oncogenic events
associated with cell cycle deregulation occurs later in plasma cell
transformation (78, 79, 115, 118).
In MGUS and early myeloma, phenotypic differentiation is not
prevented and the majority of clonal plasma cells are quiescent.
In the context of a model of irreversible cell cycle exit for nor-
mal plasma cells, the initiating oncogenic event in MGUS must
therefore be sufficient to establish an abnormal quiescent, but not
post-mitotic state, which is not observed in normal plasma cells. A
unifying model in plasma cell neoplasia has proposed that a point
of convergence for initiating events is aberrant expression of D-
type cyclins, and hence the deregulation of the cell cycle (132). The
mechanism of deregulation and the cyclin affected differs accord-
ing to the nature of the underlying molecular abnormality, but
the common event is aberrant D-type cyclin expression. Effects
on p18INK4C and other negative regulators of D-type cyclins and
G1/S phase progression are implicated in mediating the down-
stream effects of such deregulation in neoplastic plasma cells,
but the cells in the early phases of disease are minimally prolif-
erative (78). How D-type cyclin deregulation suffices to establish
an aberrant state of quiescent but not irreversible cell cycle exit,
while the capacity to fully differentiate is maintained, remains
unclear. Direct transcriptional effects of CCND1 on cell cycle gene
expression have been recently reported in other lineages and may
contribute (133, 134), but have yet to been investigated in plasma
cells.
In contrast if transit into the long-lived bone marrow plasma
cell population is linked to entry into a relative quiescent state,
accompanied by an intrinsic capacity for replicative self-renewal,
then the initiating oncogenic event in plasma cell malignancies dri-
ving D-type cyclin expression would not be required to deregulate
an entire process of irreversible cell cycle exit. Instead it would
act on a differentiated and quiescent, but not post-mitotic pop-
ulation to reduce the threshold for cell cycle re-entry. Over time
such populations would be expected to expand relative to other
long-lived plasma cells leading to gradual dominance of the clone,
but given a low overall rate of cell cycle re-entry would exhibit
slow clonal progression. Thus a relative quiescence model would
fit with the prevailing concept of plasma cell neoplasia, and would
provide a simple explanation for why small neoplastic plasma cell
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populations arise quite frequently and only progress to myeloma
at a low rate.
SUMMARY AND PERSPECTIVES
A REPLICATIVE SELF-RENEWAL MODEL OF LONG-LIVED PC
MAINTENANCE
In a replicative self-renewal model long-lived plasma cells reside
in the bone marrow niche in a quiescent state, expressing a
range of cell cycle regulators, but can be triggered by cellular
and immunological cues into undergoing transient episodes of
replicative self-renewal at a low frequency (prevalence <1% of
plasma cells) (Figure 2A). A combination of sibling-rivalry and
external competition for limited niche factors would then act to
constrain population expansion and link further long-term sur-
vival to the re-establishment of quiescence. For any individual
antigen-specificity the frequency of plasma cell replicative self-
renewal would be low, and occurring randomly would not be
predicted to result in global impact on antibody titers at any sin-
gle time-point. In the context of a plasma cell precursor with an
expressed oncogene the threshold for cell cycle re-entry would
effectively be reduced. However the plasma cell would remain con-
strained both by a requirement for physiological cues to trigger
cell cycle re-entry, and by a dependence on niche signals for sur-
vival (Figure 2B). This would be expected to result in only gradual
clonal expansion, which over time would manifest as a paraprotein
and preferential clonal representation. Additional contributory
mechanism, that have not been addressed here, could be envisaged
from expressed oncogenes conferring apoptotic resistance leading
to preferential survival of both daughter cells despite a normal
self-renewal threshold. In either case the impact of the expressed
FIGURE 2 |The replicative self-renewal model of long-lived PC
maintenance. (A) A normal quiescent plasma cell is illustrated residing in a
niche environment. The replicative self-renewal threshold is illustrated as a
dotted blue line running across a hypothetical curve representing the cell
cycle impetus in the quiescent plasma cell. The vertical axis represents the
cell cycle impetus and the horizontal axis represents time. Niche signals and
the plasma cell intrinsic program combine to establish the quiescence
threshold and oppose cell cycle re-entry. Immune and cellular cues
intermittently overcome the self-renewal threshold, leading to entry into cell
cycle, mitosis, and generation of daughter cells that compete for survival.
Successful competition for niche survival signals is linked to the
re-establishment of quiescence. Failure to compete for niche occupancy leads
to cell death limiting population expansion. (B) In an early neoplastic plasma
cell expression of an oncogene such as CCND1 (illustrated as a red line
surrounding the “nucleus”) reduces the effective replicative self-renewal
threshold by raising the steady-state level of cell cycle impetus. Dependence
on immune and cellular cues still limits cell cycle re-entry, and niche
dependence contributes to the re-establishment of quiescence. In an
alternate non-mutually exclusive scenario expression of an anti-apoptotic
oncogene (illustrated as a red line surrounding the “secretory apparatus”)
leads to preferential survival of daughter cells but the normal replicative
self-renewal threshold for cell cycle entry is retained.
www.frontiersin.org December 2013 | Volume 4 | Article 460 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tooze Plasma cell quiescence
oncogene would reflect a partial deregulation of a normal feature
of human plasma cell biology rather than a gross perturbation of
the normal differentiation process. Over time such populations
would be expected to expand relative to other long-lived plasma
cells. However, given a retained dependence on niche signals and
capacity for establishing the normal quiescent state, would only
gradually manifest as dominant clones and exhibit slow clonal
progression, thus helping to explain the population of patients
with MGUS who are at low overall risk of disease progression. The
transition to progressive disease would be expected to arise from
acquisition of additional oncogenic events eliminating the depen-
dence on physiologic cues for replicative self-renewal, delaying
re-entry into quiescence, and establishing niche independence.
PREDICTIONS OF THE MODEL
Predictions of the replicative self-renewal model would include
that: (i) a population of phenotypically mature plasma cells with
markers of cell cycle should be evident at low frequency in normal
bone marrow, these should include cells secreting antibodies spe-
cific for prior/historic vaccine immune responses, (ii) conditions
should be identifiable that promote an exit from quiescent state
and re-entry of plasma cells into short bursts of re-proliferation,
(iii) niche factors promoting plasma cell survival should support
quiescence, and alterations in these factors should impact on cell
cycle regulatory machinery as well as survival, (iv) loss of quies-
cence should be accompanied by cell death if quiescence is not
re-established, and (v) expression of myeloma associated onco-
genes should allow plasma cell differentiation and cell cycle exit
but lower the threshold for cell cycle re-entry allowing enhanced
clonal re-proliferation.
PERSPECTIVE
The model of relative quiescence and replicative self-renewal in
long-lived plasma cells is presented here as an alternative to the cur-
rently prevailing paradigm of irreversible cell cycle exit. The latter
has deep roots in plasma cell biology, and it can be argued that no
direct evidence against the prevailing paradigm currently exists,
but equally in the context of long-lived plasma cells how strong
is the evidence in its favor? Self-renewal is an established concept
amongst other memory lymphocyte populations (135, 136) and
has recently been extended to tissue resident macrophages (20–
22). While terminal differentiation is generally seen as a process
opposing such a self-renewal capacity, quiescence with the capacity
for replicative self-renewal has parallels in other cellular systems
with equivalently high functional specialization (15–19). Testing
these opposing models will provide a deeper understanding of the
nature of cell cycle exit in plasma cells, the intersection of this
process with the core plasma cell differentiation program, and the
mechanism of early plasma cell neoplasia.
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